Effect of parathyroid hormone (hPTH[1-84]) treatment on bone mass and strength in ovariectomized rats.
Skeletal fragility in osteoporotic patients is a prominent underlying cause of low-trauma fractures of most bone sites in humans. Clinical research is now focused on developing treatment strategies, including anabolic agents such as parathyroid hormone (PTH), to recover osteoporosis-related bone loss. Female Sprague-Dawley rats (4.5 mo old) were allowed to become osteopenic for 10 wk postovariectomy. Eight rats were killed at the time of ovariectomy (-10 wk) as a baseline control; sham and ovariectomized (OVX) groups were killed at wk 0. Eight rats per group (sham, OVX + vehicle, OVX + hPTH [5 d/wk], and OVX + hPTH [3 d/wk]) were killed after 4, 8, 14, and 20 wk of treatment with 50 microg/kg of human parathyroid hormone (hPTH[1-84]). Bone mineral content and density were measured only in the vertebral body. Bone strength was evaluated in the vertebral body, femoral diaphysis, femoral neck, and distal femur. Significant, lasting osteopenia developed in the vertebral body of OVX rats by 10 wk postovariectomy. Bone mineral density of the vertebral body partially recovered by 8 wk and fully recovered to that seen in sham animals only by 20 wk posttreatment with either a 5 or 3 d/wk dosing schedule of PTH[1-84]. Therefore, hPTH[1-84] (50 microg/kg) given either 3 or 5 d/wk fully restores vertebral and femoral bone strength in osteopenic OVX rats.
Akhter
M P
MP
Osteoporosis Research Center, Creighton University, Suite 4820, 601 N. 30th Street, Omaha, NE 68131, USA. akhtermp@creighton.edu
Kimmel
D B
DB
Recker
R R
RR
D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000502:physiology; D001851:Bone Diseases, Metabolic / Q000503:physiopathology*; D005260:Female; D005269:Femur / Q000502:physiology; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013131:Spine / Q000502:physiology
D010281:Parathyroid Hormone